Biology:UB-311

From HandWiki

UB-311 is a vaccine targeting β-amyloid and hence anti-amyloid agent which is under development for the treatment of Alzheimer's disease.[1][2] It is under development by Vaxxinity.[1] Meningoencephalitis has been described as a possible side effect of the drug.[3] As of February 2024, the drug is in phase 2 clinical trials.[1] In May 2022, UB-311 received fast-track designation for Alzheimer's disease from the United States Food and Drug Administration (FDA).[2]

References

  1. ↑ 1.0 1.1 1.2 "UB 311". 5 February 2024. https://adisinsight.springer.com/drugs/800032958. 
  2. ↑ 2.0 2.1 "Amyloid β-based therapy for Alzheimer's disease: challenges, successes and future". Signal Transduct Target Ther 8 (1): 248. June 2023. doi:10.1038/s41392-023-01484-7. PMID 37386015. 
  3. ↑ "Trajectory of brain-derived amyloid beta in Alzheimer's disease: where is it coming from and where is it going?". Transl Neurodegener 13 (1): 42. August 2024. doi:10.1186/s40035-024-00434-9. PMID 39160618. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Biology:UB-311&oldid=4099813"